Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced a number of presentations of data at scientific conferences.
Details of the presentations (all times PST):
AGS 2019 Annual Meeting – March 14-17, 2019, San Francisco, U.S.
Poster title: Preclinical Evaluation of NCX 4251, A Novel Steroid Therapy For Blepharitis, Targeted Directly To The Eyelid Margin To Reduce The Potential For IOP Elevations
Type: Poster session
Date: March 15, 2019 – 7:00 am to 5:00 pm
Presenter: Dr. Robert Fechtner, Chair of the Department of Ophthalmology at SUNY Upstate Medical University in Syracuse, NY
ARVO 2019 Annual Meeting –April 28-May 2, 2019, Vancouver, Canada (UNDER EMBARGO PER ARVO POLICY UNTIL 10:30 PM CET ON APRIL 30)
Poster Title: Nonclinical development of NCX 470, a novel nitric oxide (NO)-donating, IOP lowering prostaglandin analog for glaucoma and ocular hypertension
Type: Poster Session
Session Title: Pharmacologic Interventions and Cellular Mechanisms
Date: April 30, 2019 from 11:45 am to 1:30 pm
Presenter: Elena Bastia, PhD, Nicox Research Institute
Poster Title: Concomitant dosing of the NO-donor NCX 667 (1%) and Xalatan® (latanoprost ophthalmic solution 0.005%) results in robust and sustained IOP-lowering in ocular normotensive dogs)
Type: Poster Session
Session Title: Aqueous humor Dynamics and IOP
Date: April 30, 2019 from 8:45 am to 10:30 am
Presenter: Michael Bergamini, PhD, Chief Scientific Advisor, Nicox Ophthalmics, Inc.
Abstract Title: NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma
Type: Poster Session
Session Title: Pharmacologic Interventions and Cellular Mechanisms
Date: April 30, 2019 from 11:45 am to 1:30 pm
Presenter: Francesco Impagnatiello, PhD, Nicox Research Institute
Poster Title: Preclinical Evaluation of NCX 4251, a Novel Steroid Therapy for Blepharitis, Targeted Directly to the Eyelid Margin to Reduce the Potential for IOP Elevations
Type: Poster session
Session Title: Cornea Dry Eye Clinical Treatment
Date: May 2, 2019 from 10:15 am to 12:00 pm
Presenter: Tomas Navratil, PhD, Nicox Ophthalmics, Inc.